Research Index
Melanotan I (Afamelanotide) Research Index
PSI surfaces 50 peer-reviewed studies on Melanotan I (Afamelanotide), prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
Seidl-Philipp M, Schratter H, Auer J et al.
J Dtsch Dermatol Ges·2026·Human·PubMed →
Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.
Shetty N, Quiñonez RL, Ceresnie MS et al.
Photochem Photobiol·2026·Human·PubMed →
Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report.
Peshin S, Takrori E, Khan KS et al.
Reports (MDPI)·2026·Human·PubMed →
From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.
Minder AE, Barman-Aksözen J
JAAD Case Rep·2026·Human·PubMed →
Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery.
Anderson CF, Wang X, Schneider JP
J Control Release·2026·Animal·PubMed →
Biodegradable polyurethane nerve conduits functionalized with NDP-MSH-loaded self-assembling peptide hydrogels for peripheral nerve regeneration.
Li J, Wang J, Long X et al.
J Mater Chem B·2026·Animal·PubMed →
Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.
Chawathe A, Sharma N
J Pharm Biomed Anal·2026·Animal·PubMed →
New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.
Dechant C, Wäscher S, Granata F et al.
Orphanet J Rare Dis·2025·Human·PubMed →
Letter to the Editor - Qualitative evidence submitted by patients to NICE: need for more quality or unrealistic and unfair requirements?
Falchetto R, Barman-Aksözen J
J Comp Eff Res·2025·Human·PubMed →
Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis.
DerSarkissian M, Norregaard C, Romdhani H et al.
J Manag Care Spec Pharm·2025·Human·PubMed →
A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic in a tertiary referral centre.
Lai FY, Quigley C, Murray G et al.
Skin Health Dis·2025·Human·PubMed →
German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).
Homey B, Schelonke K, Schlegel CM et al.
Photodermatol Photoimmunol Photomed·2025·Human·PubMed →
Silica-Assisted Solid-Phase Peptide Synthesis (SiPPS).
Nkwanyana N, Kumar A, Chakraborty A et al.
J Pept Sci·2025·Animal·PubMed →
Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective.
Dawe RS, Kerr A, Eadie E et al.
Clin Exp Dermatol·2025·Animal·PubMed →
The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria.
Kluijver LG, Wagenmakers MAEM, Wilson JHP et al.
J Clin Endocrinol Metab·2025·Animal·Bone Healing·PubMed →
When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome-18 deletion.
Rovaris S, La Rosa G, Mezzana S et al.
Dermatol Reports·2024·Human·PubMed →
Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide.
Rhodes LE
Br J Dermatol·2024·Human·PubMed →
A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.
Jafarzadeh A, Pour Mohammad A, Khosravi M et al.
Skin Res Technol·2024·Human·PubMed →
Erythropoietic protoporphyria and afamelanotide: a patient's perspective.
O'Reilly M, McGuire VA, Dawe RS
Clin Exp Dermatol·2024·Human·PubMed →
Discovery of MT-7117 (Dersimelagon Phosphoric Acid): A Novel, Potent, Selective, and Nonpeptidic Orally Available Melanocortin 1 Receptor Agonist.
Sato A, Morokuma K, Adachi T et al.
J Med Chem·2024·Animal·Wound Healing·PubMed →
Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation.
Mittapelly N, Djehizian A, Telaprolu KC et al.
ACS Appl Bio Mater·2024·Animal·PubMed →
Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).
Weirath NA, Haskell-Luevano C
ACS Pharmacol Transl Sci·2024·Animal·PubMed →
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.
Suzuki S, Kitanaka C, Okada M
Anticancer Res·2024·Animal·PubMed →
Melanocortin-receptor 4 activation modulates proliferation and differentiation of rat postnatal hippocampal neural precursor cells.
Carniglia L, Turati J, Saba J et al.
Neuropharmacology·2024·Animal·PubMed →
Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort.
Leaf RK, Naik H, Jiang PY et al.
Life (Basel)·2024·Animal·PubMed →
Quality of life in children with erythropoietic protoporphyria: a case-control study.
Kluijver LG, Wensink D, Wagenmakers MAEM et al.
J Dermatol·2024·Animal·PubMed →
Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England.
Barman-Aksözen J, Hentschel N, Pettersson M et al.
Int J Environ Res Public Health·2024·Animal·PubMed →
A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.
Stanislaus V, Kam A, Murphy L et al.
BMC Neurol·2023·Human·PubMed →
Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study.
Barman-Aksözen J, Minder AE, Granata F et al.
Int J Environ Res Public Health·2023·Human·PubMed →
Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study.
Ceresnie MS, Mohney L, Ko D et al.
J Am Acad Dermatol·2023·Human·PubMed →
Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study.
Wensink D, Wagenmakers MAEM, Qi H et al.
Mol Genet Metab·2022·Human·PubMed →
Liver involvement in patients with erythropoietic protoporphyria.
Wensink D, Coenen S, Wilson JHP et al.
Dig Liver Dis·2022·Human·PubMed →
Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.
Minder AE, Barman-Aksoezen J, Schmid M et al.
Ther Adv Rare Dis·2021·Human·PubMed →
Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.
Wensink D, Langendonk JG, Overbey JR et al.
Genet Med·2021·Human·PubMed →
Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide.
Arisi M, Rossi M, Rovati C et al.
Photochem Photobiol Sci·2021·Human·PubMed →
Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.
Barman-Aksözen J, Nydegger M, Schneider-Yin X et al.
Orphanet J Rare Dis·2020·Human·Wound Healing·PubMed →
Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice.
Wensink D, Wagenmakers MAEM, Barman-Aksözen J et al.
JAMA Dermatol·2020·Human·PubMed →
Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.
Toh JJH, Chuah SY, Jhingan A et al.
J Am Acad Dermatol·2020·Human·PubMed →
Patients with porphyria bask in sunlight of FDA approval.
Ratner M
Nat Biotechnol·2019·Human·PubMed →
Afamelanotide for Erythropoietic Protoporphyria.
Langendonk JG, Balwani M, Anderson KE et al.
N Engl J Med·2015·Human·PubMed →
Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.
Biolcati G, Marchesini E, Sorge F et al.
Br J Dermatol·2015·Human·PubMed →
Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies.
Lengweiler S, Kreim S, Barman-Aksözen J et al.
Skin Pharmacol Physiol·2015·Human·PubMed →
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
Lim HW, Grimes PE, Agbai O et al.
JAMA Dermatol·2015·Human·PubMed →
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease.
Biolcati G, Aurizi C, Barbieri L et al.
Clin Exp Dermatol·2014·Human·PubMed →
Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris.
Böhm M, Ehrchen J, Luger TA
J Eur Acad Dermatol Venereol·2014·Human·PubMed →
A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria.
Spichty R, Balimann M, Barman J et al.
J Pharm Biomed Anal·2013·Human·PubMed →
Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.
von Bartenwerffer W, Siebenhaar G, Hunzelmann N
Acta Derm Venereol·2011·Human·PubMed →
Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH.
Haylett AK, Nie Z, Brownrigg M et al.
Br J Dermatol·2011·Human·Wound Healing·PubMed →
Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal.
Minder EI, Schneider-Yin X, Minder CE
Health Qual Life Outcomes·2010·Human·PubMed →
Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.
Harms JH, Lautenschlager S, Minder CE et al.
Photochem Photobiol·2009·Human·PubMed →